Key TakeawaysSingapore's Drew & Napier is set to file claims against the Swiss government, seeking approximately $300 million in compensation for 560 Asian bondholders impacted by the 2023 Credit Suisse AT1 debt wipeout, following a recent Swiss court ruling that deemed the write-down unlawful.AstraZeneca's (AZN) and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has demonstrated a significant 5.0-month improvement in overall survival in aggressive triple-negative breast cancer (TNBC) patients, marking ...

AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near Charlottesville, will produce APIs for medicines across its cardiovascular, obesity, oncology and metabolic disease portfolio. This includes drugs from the company’s mid-to-late-stage pipeline – namely its Eccogene-partnered glucagon-like peptide-1 receptor agonist (GLP-1RA) pill, AZD5004/ ECC-5004, as well as hypertension med baxdrostat and low-d ...